VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to establish the maximally tolerated dose of VELCADE
that can be administered with idarubicin and cytarabine in patients with AML. The secondary
objectives of this study are assessment of efficacy, safety, and pharmacokinetics of Velcade
when combined with Cytarabine and idarubicin. Various molecular markers associated with
response to Velcade, cytarabine, and idarubicin will be explored by utilizing microarray
analyses. The study endpoints are maximum tolerated dose and response to treatment.